Richard H. Stanford, PharmD, MS
Articles
COPD Exacerbation Costs in the IMPACT Study: A Within-Trial Analysis
Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT
This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.
Claims-Based Risk Model for First Severe COPD Exacerbation
A health insurance claims-based risk assessment tool to predict patients’ first severe chronic obstructive pulmonary disease exacerbation has been developed and validated.
Predicting Asthma Outcomes in Commercially Insured and Medicaid Populations
The controller-to-total asthma medication ratio was a significant predictor of exacerbations in pediatric and adult commercially insured and Medicaid patients.
